Literature DB >> 6198272

Antigen-specific HLA-restricted human T-cell lines. I. An MT3-like restriction determinant distinct from HLA-DR.

E J Ball, P Stastny.   

Abstract

The results presented provide evidence that the HLA specificity known as MT3, BR4, or Hon7 can serve as a restriction epitope for the proliferation of certain T cells responding to mumps viral antigen. This restriction determinant was found to be HLA-linked in family studies, and to segregate centromeric to a crossover between HLA-B and DR in one family. In the population studied, the specificity was found to be associated with the DR antigens DR4, DR7, and DRw9, which are known to be associated with MT3. The ability of accessory cells to present mumps antigen in the context of this supertypic restriction determinant was blocked by a monoclonal antibody specific for MT3. Since MT3 (BR4, Hon7) has been shown to be expressed on molecules distinct from DR, our experiments suggest that such molecules are functionally important in antigen presentation to T cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198272     DOI: 10.1007/bf00364472

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  33 in total

1.  T lymphocyte-enriched murine peritoneal exudate cells. III. Inhibition of antigen-induced T lymphocyte Proliferation with anti-Ia antisera.

Authors:  R H Schwartz; C S David; D H Sachs; W E Paul
Journal:  J Immunol       Date:  1976-08       Impact factor: 5.422

2.  Inhibition of dual Ir gene-controlled T-lymphocyte proliferative response to poly (Glu56Lys35Phe9)n with anti-Ia antisera directed against products of either I-A or I-C subregion.

Authors:  R H Schwartz; C S David; M E Dorf; B Benacerraf; W E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

3.  Polymorphism of human B-cell alloantigens: evidence for three loci within the HLA system.

Authors:  M L Markert; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

4.  Split of HLA-D into two regions alpha and beta by a recombination between HLA-D and GLO. I. Study in a family and primed lymphocyte typing for determinants coded by the beta region.

Authors:  C Mawas; D Charmot; P Mercier
Journal:  Tissue Antigens       Date:  1980-05

Review 5.  The human immune response region (HLA-D) and disease susceptibility.

Authors:  P Stastny; E J Ball; P J Dry; G Nunez
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

6.  SB: a new HLA-linked human histocompatibility gene defined using HLA-mutant cell lines.

Authors:  P Kavathas; R DeMars; F H Bach; S Shaw
Journal:  Nature       Date:  1981-10-29       Impact factor: 49.962

7.  Two populations of Ia-like molecules on a human B cell line.

Authors:  L A Lampson; R Levy
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

8.  Macrophage-dependent response of immune human T lymphocytes to PPD in vitro. Influence of HLA-D histocompatibility.

Authors:  B O Bergholtz; E Thorsby
Journal:  Scand J Immunol       Date:  1977       Impact factor: 3.487

9.  Evidence for a new segregant series of B cell antigens that are encoded in the HLA-D region and that stimulate secondary allogenic proliferative and cytotoxic responses.

Authors:  S Shaw; A H Johnson; G M Shearer
Journal:  J Exp Med       Date:  1980-09-01       Impact factor: 14.307

10.  Monoclonal antibody against an Ir gene product?

Authors:  E A Lerner; L A Matis; C A Janeway; P P Jones; R H Schwartz; D B Murphy
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  9 in total

1.  Recognition of class II molecules by human T cells. I. Analysis of epitopes of DR and DQ molecules in a DRw11, DRw52, DQw3 haplotype.

Authors:  L K Myers; E J Ball; G Nuñez; P Stastny
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

2.  Molecular characterization of MT3 antigens by two-dimensional gel electrophoresis, NH2-terminal amino acid sequence analysis, and southern blot analysis.

Authors:  R Sorrentino; J Lillie; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

3.  An antiviral T-cell clone defines a functional supertypic specificity shared by different HLA-DR molecules from DR2-short, DRw11, and DRw13 haplotypes.

Authors:  D Zeliszewski; G Sterkers; J Choppin; C Freidel; L Gebuhrer; H Betuel; J P Levy
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

4.  Strong association of rheumatoid arthritis with the presence of a polymorphic Ia epitope defined by a monoclonal antibody: comparison with the allodeterminant DR4.

Authors:  S H Lee; P K Gregersen; H H Shen; A Nunez-Roldan; J Silver; R J Winchester
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

5.  Molecular characterization of a subtype of DQw1 recognized by hapten-specific T cells.

Authors:  J H Hanke; R G Cook; J W Leone; M Van; R R Rich
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

6.  Close association between the Dw14 (LD40) subtype of HLA-DR4 and a restriction element for antigen-specific T-cell clones.

Authors:  E Qvigstad; E Thorsby; N L Reinsmoen; F H Bach
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

7.  Antigen-specific HLA-restricted human T-cell lines. II. A GAT-specific T-cell line restricted by a determinant carried by an HLA-DQ molecule.

Authors:  E J Ball; P Stastny
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

8.  Molecular localization of human class II MT2 and MT3 determinants.

Authors:  C K Hurley; R C Giles; G Nunez; R DeMars; L Nadler; R Winchester; P Stastny; J D Capra
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 17.579

9.  Molecular localization and polymorphism of HLA class II restriction determinants defined by Mycobacterium leprae-reactive helper T cell clones from leprosy patients.

Authors:  T H Ottenhoff; S Neuteboom; D G Elferink; R R de Vries
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.